The Zhitong Finance App learned that Hengrui Pharmaceutical (01276) rose more than 4% at the end of the session. As of press release, it had risen 3.9% to HK$58.6, with a turnover of HK$220 million.

According to the news, on August 6, Hengrui Pharmaceutical announced that the third indication for injectable Ruikang trastuzumab was approved for marketing, making it the first anti-HER2 product approved for colorectal cancer in China. This indication is for adult patients with HER2-positive colorectal cancer who have failed treatment with oxaliplatin, fluorouracil, and irinotecan. The drug has previously been approved for use in both non-small cell lung cancer and breast cancer.

It is worth noting that in June of this year, Hengrui Pharmaceutical's Cyclosporine Eye Drops IV (Hengyi) was marketed to treat decreased tear production caused by dry eyes. As the first and only 0.1% anhydrous cyclosporine eye drop in China, this product brings multiple therapeutic advantages and is expected to lead clinical drug iterations. The company's ophthalmology layout is entering a harvest period as a number of innovative products have been approved for launch.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.